Karimi-Haghighi Saeideh, Pandamooz Sareh, Jurek Benjamin, Fattahi Sadegh, Safari Anahid, Azarpira Negar, Dianatpour Mehdi, Hooshmandi Etrat, Bayat Mahnaz, Owjfard Maryam, Zafarmand Seyedeh Shaghayegh, Mostaghel Mandana, Mousavi Seyedeh Maryam, Jashire Nezhad Nahid, Eraghi Vida, Fadakar Nima, Rahimi Jaberi Abbas, Garcia-Esperon Carlos, Spratt Neil, Levi Christopher, Salehi Mohammad Saied, Borhani-Haghighi Afshin
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mol Neurobiol. 2023 May;60(5):2587-2601. doi: 10.1007/s12035-023-03223-z. Epub 2023 Jan 24.
The short-term therapeutic impacts of stem cells and their derivatives were frequently reported in preclinical investigations of ischemic stroke (IS); however, several drawbacks including accessibility, abundancy, and ethical concerns limited their clinical application. We describe here for the first time the therapeutic potential of human hair follicle-derived stem cells (hHFSCs) and their conditioned medium (CM) in a rat model of IS. Furthermore, we hypothesized that a combination of cell therapy with repeated CM administration might enhance the restorative efficiency of this approach compared to each treatment alone. Middle cerebral artery occlusion was performed for 30 min to induce IS. Immediately after reperfusion, hHFSCs were transplanted through the intra-arterial route and/or hHFSC-CM administered intranasally. The neurological outcomes, short-term spatial working memory, and infarct size were evaluated. Furthermore, relative expression of seven target genes in three categories of neuronal markers, synaptic markers, and angiogenic markers was assessed. The hHFSCs and hHFSC-CM treatments improved neurological impairments and reduced infarct size in the IS rats. Moreover, molecular data elucidated that IS was accompanied by attenuation in the expression of neuronal and synaptic markers in the evaluated brain regions and the interventions rescued these expression changes. Although there was no considerable difference between hHFSCs and hHFSC-CM treatments in the improvement of neurological function and decrement of infarct size, combination therapy was more effective to reduce infarction and elevation of target gene expression especially in the hippocampus. These findings highlight the curative potential of hHFSCs and their CM in a rat model of IS.
在缺血性中风(IS)的临床前研究中,经常报道干细胞及其衍生物的短期治疗效果;然而,包括可及性、丰度和伦理问题在内的几个缺点限制了它们的临床应用。我们首次在此描述人毛囊来源的干细胞(hHFSCs)及其条件培养基(CM)在IS大鼠模型中的治疗潜力。此外,我们假设与单独的每种治疗相比,细胞疗法与重复给予CM相结合可能会提高这种方法的恢复效率。进行大脑中动脉闭塞30分钟以诱导IS。再灌注后立即通过动脉内途径移植hHFSCs和/或经鼻给予hHFSC-CM。评估神经学结果、短期空间工作记忆和梗死面积。此外,评估了三类神经元标志物、突触标志物和血管生成标志物中七个靶基因的相对表达。hHFSCs和hHFSC-CM治疗改善了IS大鼠的神经功能障碍并减小了梗死面积。此外,分子数据表明,IS伴随着评估脑区中神经元和突触标志物表达的减弱,而这些干预措施挽救了这些表达变化。尽管hHFSCs和hHFSC-CM治疗在改善神经功能和减小梗死面积方面没有显著差异,但联合治疗在减少梗死和提高靶基因表达方面更有效,尤其是在海马体中。这些发现突出了hHFSCs及其CM在IS大鼠模型中的治疗潜力。